Noradrenergic dysfunction in the prefrontal cortex in depression:: An [15O] H2OPET study of the neuromodulatory effects of clonidine

Background: Noradrenergic dysfunction has been consistently implicated in depression. Much of the evidence, though, has been indirect, such as an attenuated growth hormone response to the alpha (2)-adrenoceptor agonist clonidine. To more directly examine central functioning of the noradrenergic system in depression, we have used [O-15] H2O positron emission tomography (PET) to measure cerebral blood flow (rCBF) in combination with clonidine as a neuromodulatory probe. Methods: Subjects were six depressed and six healthy women, medication free and matched for age and phase of menstrual cycle. Two PET scans were acquired at baseline and two scans at 20 and 35 min following an intravenous clonidine infusion of 1.4 mug/kg while subjects performed a sustained attention task. Results: The growth hormone response did not show a significant difference between groups. However, PET results revealed a difference in the right superior prefrontal cortex that was resolved as an interaction from decreased rCBF in healthy control subjects but increased rCBF in the depressed group, which was not accounted for by differences in task performance. Conclusions: This differential effect of clonidine in the right prefrontal cortex provides in vivo evidence of noradrenergic gic dysfunction in depression, which we postulate arises from functionally impaired presynaptic alpha (2)-adrenoceptors as well as regionally "supersensitive" postsynaptic cortical alpha (2)-adrenoceptors. (C) 2001 Society of Biological Psychiatry.